Niowave Lansing site to scale Ac-225 supply by 2028
The Lansing, MI, site will house superconducting linear accelerators and radiochemistry systems to support scalable actinium-225 production, with completion expected in 2028.
Niowave has broken ground on a $75M actinium-225 production facility in Lansing, MI, according to AuntMinnie. It is the company’s 2nd dedicated production site in the city.
The site will include multiple proprietary superconducting linear accelerators, processing systems, and quality systems to support scalable Ac-225 production. Construction is being led by the Christman Company in collaboration with Colliers Engineering & Design, with completion expected in 2028.
Ac-225 is an alpha-emitting isotope used in targeted cancer therapies. Niowave describes Ac-225 as a radioisotope used in treatments designed to selectively destroy cancer cells while limiting damage to surrounding healthy tissue.
Niowave said the new facility is expected to create about 70 jobs. The Lansing-based company has signed major Ac-225 supply agreements with AstraZeneca and Novartis in recent months.
In February, Niowave said its Novartis agreement would support expanded production capacity and that it intended to begin construction of a new Lansing manufacturing facility in early 2026. The company said the agreement would provide Novartis with scalable Ac-225 supply for its radioligand therapy portfolio.
Niowave’s 20-year company update said its 2026 facility plans included 6 accelerators and radiochemistry systems, with Ac-225 production capacity beyond 175 Ci per year. The company said it employs about 180 people and operates facilities in Lansing.
Company:Niowave
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
30-year GE-UW tie expands into CT and theranostics research
The collaboration will focus on CT and molecular imaging technologies for cardiology, oncology, and theranostics workflows at UW Medicine Radiology facilities in Seattle.
Recall issues and isotope shortages weigh on Radnostix Q1 revenue
The radioisotope-focused company reported $2.38M in Q1 revenue, citing recall impacts, isotope shortages, and Cobalt-60 hot cell downtime.
Ephemeral to build AI data platform for Plus CNS oncology programs
The companies will develop an AI platform to integrate therapeutic, diagnostic, and bioinformatics data across Plus Therapeutics’ CNS oncology programs.
Fujifilm balloon-free EBUS scope targets pulmonary setup time
The EB-710US Ultrasound Bronchoscope is designed for pulmonary procedures and will be demonstrated at the American Thoracic Society Conference.
ACIST Pro brings contrast tracking upgrade to U.S. cath labs
The Bracco company received U.S. clearance and launched ACIST Pro, a variable-rate contrast management system for image-guided cardiovascular procedures.
Braid Health launches $199 radiology second-opinion service
Patients can upload MRI, CT, X-ray, or ultrasound files and receive a written second opinion from a board-certified U.S. radiologist.
QT Imaging prices $10M raise for breast imaging platform
QT Imaging Holdings priced a $10M underwritten public offering of common stock and pre-funded warrants. The breast imaging technology company plans to use proceeds for working capital and general corporate purposes.
PSMA PET guidance anchors EDAP-Telix HIFU prostate work
EDAP TMS and Telix Pharmaceuticals signed a letter of intent to explore clinical research combining Focal One Robotic HIFU with Telix PSMA PET imaging agents in prostate cancer care.
UnitedHealthcare cites radiology costs in Maryland premium request
UnitedHealthcare is seeking an average 7.9% mid-year premium increase for some Maryland small-group plans. The insurer cited rising outpatient costs, including radiology, lab pathology, infusion, and radiation therapy.
Lumexa adds 4 imaging centers, including first UPMC JV site
Lumexa Imaging added 4 outpatient imaging centers across Pennsylvania, North Carolina, South Carolina, and Florida. The expansion includes acquired centers through joint ventures with UPMC and Advocate Health, plus 2 newly built locations.
PAI report finds 82% of U.S. physicians are now employed
A new PAI-Avalere report found that 82% of U.S. physicians are employed by hospitals, health systems, or corporate entities. Physician-owned settings now account for 18% of physicians and 36.1% of practices.
TerraPower breaks ground on Ac-225 isotope facility
TerraPower Isotopes has broken ground on a $450M actinium-225 manufacturing facility in Philadelphia. The company said the site will increase global Ac-225 production capacity 20-fold.